在新的 Trial Simulator 中模拟病毒动力学
Watch this webinar to learn how to use simulation to anticipate risks and preview the range of possible trial results before millions of R&D dollars are spent exposing subjects to experimental therapies.
Month: February 2019
How to Perform IVIVC for Extremely Long Acting Drugs
Watch this webinar to learn how to use in vitro and in vivo models to find direct time scaling factors and confirm the similarity of the in vitro and in vivo release mechanisms.
Managing Immunogenicity Using Quantitative Systems Pharmacology
The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving sector in the biopharmaceutical industry. Biologically-based therapeutic drugs comprise monoclonal antibodies (MAbs), vaccines, recombinant hormones and proteins, antibody-drug conjugates, RNAi, antisense, blood factors, and other large molecules. Although the success of biologics has been demonstrated, there are inherent operational and … Continued
Certara Launches Version 19.1 of its D360 Scientific Informatics Platform
PRINCETON, NJ – 2019 年 2 月 21 日 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.
Certara Advances Global Initiative to Take Model-Informed Precision Dosing (MIPD) Into the Clinic
PRINCETON, NJ – 2019 年 2 月 7 日 – Certara has recently published four peer-reviewed MIPD papers; its progress is generating strong interest from industry, health care professionals and regulators.
PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions
This white paper addresses common PBPK myths and misconceptions and demonstrates how this approach is an industrial and regulatory necessity in modern drug development.
Certara Appoints Justin Edge as President of its Synchrogenix Division
PRINCETON, NJ – 2019 年 2 月 4 日 – Certara today announced that Justin Edge has joined Certara as President of Synchrogenix, the company’s regulatory science division.
1 of 1
